4 February 2021

MaxCyte announces £40 million subscription

MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, has raised gross proceeds of £40 million (US$55 million) through a private placement of common stock. Subscribers included new investors D1 Capital Partners, T. Rowe Price, ArrowMark Partners, Baron Capital Group and First Light Asset Management, alongside existing investors Casdin Capital and Sofinnova Partners.

Doug Doerfler, President & Chief Executive Officer of MaxCyte, expressed his delight at the new life science specialist investors. He said that the financing would strengthen the company's balance sheet as it accelerates revenue growth in 2021 and marked a further step towards the company's goal to dual-list on Nasdaq in 2021.

There has been a 464.5% increase in the company's share price over the last 12 months, indicating strong investor interest in genomics and asset allocations to life sciences. MaxCyte's Flow Electroporation® Technology enables its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy.

Working with Panmure Gordon, LGB introduced investors to MaxCyte's fundraisings in 2017 and 2019. The fundraisings, which benefitted from EIS, were conducted at 275p and 170p per share respectively. The placing just announced was conducted at 700p.


Recent Articles

14 April 2021

Sema Lease - Limit Increase

LGB Capital Markets arranged a £35 million Medium Term Note (MTN) programme for Sema Lease UK Limited (Sema), the short-term vehicle leasing provider.

Read more


6 April 2021

Private debt funds are attractive, but they aren’t a straight route to strong returns

With the pandemic rendering conventional equity-bond portfolios unfit to generate stable yields, investors are increasingly turning to private debt funds – vehicles that lend to busine Read more

News & Insights

26 March 2021

A Brief Dive Into Private Credit Investing

Private debt has been a principal beneficiary of measures to tackle the COVID-19 pandemic. Read more

News & Insights